JPRN-jRCT2031260267 Precemtabart tocentecan Metastatic Colorectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready landscape. This focused report examines JPRN-jRCT2031260267—A randomized, open label, 3-arm Phase 3 study of precemtabart tocentecan with or without bevacizumab compared to trifluridine/tipiracil plus bevacizumab in participants with previously treated metastatic colorectal cancer (PROCEADE-CRC-03)—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why JPRN-jRCT2031260267 is a hot trial to watch
Metastatic Colorectal Carcinoma is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. JPRN-jRCT2031260267 is notable because it evaluates Precemtabart tocentecan in a Phase 3 design while Arm 1, 2 and 3: Overall Survival (OS) [ Time Frame: Time from date of randomization to death, assessed approximately upto average of 19 months ] Overall survival (OS), defined as the time from randomization to death. serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.
PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | JPRN-jRCT2031260267 |
| Official title | A randomized, open label, 3-arm Phase 3 study of precemtabart tocentecan with or without bevacizumab compared to trifluridine/tipiracil plus bevacizumab in participants with previously treated metastatic colorectal cancer (PROCEADE-CRC-03) |
| Phase / status | Phase 3 / 募集中 |
| Intervention | Precemtabart tocentecan, Trifluridine, Bevacizumab |
| Sponsor | Merck Biopharma Co., Ltd. |
| Collaborators | Not reported |
| Geography | United States, Japan |
| Enrollment | 80 |
| Primary endpoint | Arm 1, 2 and 3: Overall Survival (OS) [ Time Frame: Time from date of randomization to death, assessed approximately upto average of 19 months ] Overall survival (OS), defined as the time from randomization to death. |
| Endpoint time frame | Not reported |
| Primary completion / readout proxy | [object Object] |
Design and endpoint interpretation
The phase label is only the starting point. Allocation is Randomized, masking is Open Label, and the intervention model is Parallel Assignment. Planned enrollment of 80 participants across United States, Japan shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary: Arm 1, 2 and 3: Overall Survival (OS) [ Time Frame: Time from date of randomization to death, assessed approximately upto average of 19 months ] Overall survival (OS), defined as the time from randomization to death.
- Primary: 第1、2および3群：全生存期間（OS）［評価期間：無作為化日から死亡までの期間、平均約19か月まで評価）］ 全生存期間（OS）は、無作為化から死亡までの期間として定義される。
Benchmark readouts in the surrounding field
- The Role of Neutrophil Mitochondrial Dysfunction in Medical Rehabilitation During Palliative Chemotherapy for Metastatic Colorectal Cancer (Phase 2/3): Relative Dose Intensity of FOLFOX(Mean) = 59.7 percentage (Standard Deviation, 18.9); Relative Dose Intensity of FOLFOX(Mean) = 78.4 percentage (Standard Deviation, 15.2)
- AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER (Phase 3): SLI: Number of Participants With Dose Limiting Toxicity (DLTs) = 0 Participants ; SLI: Number of Participants With Dose Limiting Toxicity (DLTs) = 1 Participants
- Liposomal irinotecan combined with 5-FU/LV and bevacizumab as second-line therapy for metastatic colorectal cancer: A multicenter, single-arm phase II study (IRIS). (Phase 2): ORR = 18.0 % ( 11.4 - 26.4)
These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.
Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: Precemtabart tocentecan (Phase 3; CEACAM5 x Top I); Trifluridine (Approved; DNA-directed DNA polymerase); Bevacizumab (Approved; VEGF-A)
Company & Deal Intelligence context: Merck Biopharma Co., Ltd. — Japan — https://www.merckgroup.com
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: comparative data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.
Bottom line
JPRN-jRCT2031260267 is a focused lens on Metastatic Colorectal Carcinoma development. Its value will be determined by whether Precemtabart tocentecan can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
